Latest News - Alimera Sciences

Wednesday, November 08, 2017 | Conferences, Alimera Sciences, American Academy of Ophthalmology

Alimera Sciences Announces Nine Iluvien Data Sets To Be Presented at 2017 American Academy of Ophthalmology

Alimera Sciences announced that data from nine Iluvien studies have been accepted for presentation during the 2017 Annual Meeting of the American Academy of Ophthalmology (AAO) at the Ernest N. Morial…

Read the full story

Tuesday, October 03, 2017 | Conferences, Retina, Alimera Sciences

Alimera Sciences Announces Four Data Sets for Iluvien to Be Presented at 2017 Retina Society’s Annual Meeting

Alimera Sciences announced that four Iluvien data sets will be presented during the 2017 Annual Meeting of the Retina Society to be held October 5-8 at the Fairmont Copley Plaza Hotel in Boston. &q…

Read the full story

Monday, September 11, 2017 | Retina, Alimera Sciences

Illuvien Now Available in Ireland for the Treatment of Chronic DME

Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) is being made available in Ireland following an agreement between the healthcare provider Vhi and Iluvien’s …

Read the full story

Tuesday, July 25, 2017 | Medical Studies, Retina, Alimera Sciences

New Data Reveal Real-World Benefits of Iluvien Treatment

Latest data from an ongoing audit of real-life UK clinical practice published online in the journal Eye show the number of chronic diabetic macular edema (DME) patients with 6/12 vision, DVLA’s …

Read the full story

Thursday, July 20, 2017 | Clinical Trials, Alimera Sciences

Positive Results Enable Alimera Sciences to Reduce Enrollment in Iluvien Registry Safety Study in the UK

Alimera Sciences announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has given final approval to reduce the size of its Iluvien Registry Safety…

Read the full story

Tuesday, July 11, 2017 | Alimera Sciences, Psivida

Alimera Sciences To Expand Iluvien Indication in Europe for Posterior Uveitis

Alimera Sciences announced that it secured the rights to pursue posterior uveitis, a secondary indication for Iluvien, in the European Union (EU), the Middle East and Africa.  Alimera secured …

Read the full story

Monday, May 01, 2017 | Conferences, Alimera Sciences

Alimera Sciences Announces Data From 27 Iluvien Studies to be Presented at ARVO

Alimera Sciences announced that data from 25 Iluvien pivotal and post-marketing studies and two presentations on diabetic retinopathy have been accepted for presentation during the 2017 Annual Meeting…

Read the full story

Thursday, February 23, 2017 | Partnerships, Alimera Sciences

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien in Canada

Alimera Sciences and Knight Therapeutics, a Canadian specialty pharmaceutical company, announced that Knight's New Drug Submission (NDS) for Iluvien has been accepted for review by Health Canada. …

Read the full story

Wednesday, February 22, 2017 | Medical Studies, Alimera Sciences

Iluvien Implants Yield 12-month Benefit for Diabetic Macular Edema

The anatomical and visual benefits of intravitreal fluocinolone acetonide implants in patients with chronic diabetic macular edema (DME) persist up to 12 months, a small study suggests. The efficacy a…

Read the full story

Monday, February 06, 2017 | Earnings & Financials, Alimera Sciences

Alimera Sciences Announces the Reimbursement of Iluvien in Italy

Alimera Sciences announced that it has received the pricing and reimbursement decree for Iluvien from Agenzia Italiana del Farmaco (AIFA) on January 11, 2017. The decree, published February 2, 2017, i…

Read the full story

Wednesday, October 26, 2016 | Product Releases, Alimera Sciences

Alimera Sciences Begins Selling Iluvien in the Middle East

Alimera Sciences announced that its subsidiary, Alimera Sciences B.V., has begun shipping Iluvien, an eye implant for the treatment of diabetic macular edema (DME), to MEAgate International FZLLC, hea…

Read the full story

Tuesday, August 09, 2016 | Conferences, Alimera Sciences

Alimera Sciences Announces Clinical Presentations and Sponsored Symposia at ASRS 2016

Alimera Sciences announced that data from three Iluvien postmarketing studies will be presented during the American Society of Retinal Physicians (ASRS) 2016 Annual Meeting, August 10-14, in San Franc…

Read the full story

Tuesday, May 24, 2016 | Clinical Trials, Alimera Sciences

Majority of Chronic DME Patients Gain or Maintain Vision with Single Iluvien Injection Injection at 12 Months

Two real world data sources, revealed at the Royal College of Ophthalmologists (RCOphth) Annual Congress, show that the majority of chronic diabetic macular edema (DME) patients who received a single …

Read the full story

Wednesday, May 11, 2016 | Medical Studies, Alimera Sciences

Alimera Sciences' Iluvien Data Presented at SFO 2016

Alimera Sciences announced that data from six Iluvien post-marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10, according to a compa…

Read the full story

Friday, May 06, 2016 | Conferences, Retina, Alimera Sciences

Alimera Sciences' Iluvien Data Presented at ARVO

Alimera Sciences announced that data from seven Iluvien post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seatt…

Read the full story
Load More